Investors Purchase High Volume of BioNTech Put Options (NASDAQ:BNTX)

BioNTech SE Sponsored ADR (NASDAQ:BNTX) saw some unusual options trading activity on Friday. Traders purchased 4,317 put options on the company. This represents an increase of 119% compared to the typical volume of 1,972 put options.

BioNTech Trading Down 8.4%

Shares of BioNTech stock opened at $102.07 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a market capitalization of $25.81 billion, a P/E ratio of -13.04 and a beta of 1.27. The business has a 50 day moving average price of $95.40 and a 200 day moving average price of $95.89.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the company posted ($1.60) EPS. Sell-side analysts anticipate that BioNTech will post -6.33 EPS for the current fiscal year.

BioNTech announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Flossbach Von Storch SE purchased a new position in BioNTech in the 2nd quarter valued at about $207,142,000. BNP Paribas Financial Markets grew its holdings in shares of BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after buying an additional 474,796 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares in the last quarter. GSK plc acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $84,711,000. Finally, First Trust Advisors LP raised its position in shares of BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted COMIRNATY vaccine for the 2026–2027 season. Shipping is beginning immediately, potentially supporting near-term seasonal revenue and maintaining the product’s commercial presence. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: One investment analysis reiterated a Strong Buy rating, citing momentum in BioNTech’s late-stage oncology pipeline, strategic partnerships, and upcoming catalysts for gotistobart and pumitamig. Expected data at WCLC 2026 could help refocus investor attention on the company’s long-term growth prospects. BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
• Neutral Sentiment: Options activity was unusually bearish, with put purchases more than doubling typical volume. This signals heightened hedging or speculative downside expectations, but does not by itself establish a change in BioNTech’s fundamentals.
• Negative Sentiment: BioNTech decided to terminate a Phase 2 trial of autogene cevumeran in colorectal cancer. The setback weakens confidence in the company’s personalized mRNA cancer-vaccine strategy and removes a clinical catalyst, overshadowing the COMIRNATY approval. BioNTech to terminate mid-stage trial of mRNA cancer vaccine
• Negative Sentiment: The trial discontinuation triggered a sharp decline in the stock and raised concerns about the risks facing BioNTech’s oncology pipeline. Investors also remain cautious because COVID-19 vaccine demand and competition are pressuring revenue expectations, even as the XFG formulation expands COMIRNATY’s seasonal opportunity. BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer

Analysts Set New Price Targets

Several research firms recently weighed in on BNTX. Berenberg Bank dropped their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $117.00 to $135.00 in a research report on Wednesday, May 27th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup decreased their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $127.81.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.